Co-sponsors of the 2018 Genitourinary Cancers Symposium announced today four abstracts to be highlighted in the meeting’s official Press Program.
The following studies will be featured:
- A randomized, phase III trial investigating the hormone therapy apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer, a form of prostate cancer currently with no approved therapies (Abstract 161).
- An analysis of health-related quality of life and cost-effectiveness when docetaxel is added to first-line hormone therapy for prostate cancer (Abstract 162).
- A study evaluating a prognostic model to predict overall survival for patients with advanced bladder cancer receiving the immunotherapy atezolizumab (Abstract 413).
- A randomized, phase III trial of atezolizumab plus bevacizumab versus sunitinib for first-line treatment of advanced kidney cancer (Abstract 578).